Overview
Peters anomaly is a rare congenital eye disorder classified as an anterior segment dysgenesis. It is characterized by a central corneal opacity (leukoma) present at birth, along with defects in the posterior layers of the cornea (Descemet membrane and endothelium) and adhesions (synechiae) between the iris and the cornea. The condition primarily affects the anterior segment of the eye and can lead to significant visual impairment or blindness if untreated. Peters anomaly is typically divided into two types: Type I involves central corneal opacity with iridocorneal adhesions but without lens involvement, while Type II includes corneolenticular adhesions or contact, often with cataracts and more severe visual compromise. The condition may be unilateral or bilateral, with bilateral cases tending to be more severe. Peters anomaly can occur as an isolated ocular finding or as part of a broader syndrome known as Peters plus syndrome, which includes short stature, brachydactyly, developmental delay, and characteristic facial features. Isolated Peters anomaly has been associated with mutations in several genes involved in anterior segment development, including PAX6, PITX2, PITX3, FOXC1, FOXE3, and CYP1B1. Peters plus syndrome is caused by mutations in the B3GLCT gene. Glaucoma is a frequent and serious complication, occurring in approximately 50-70% of affected individuals, and can be difficult to manage. Treatment of Peters anomaly is challenging and often requires a multidisciplinary approach. Corneal transplantation (penetrating keratoplasty) may be performed to restore corneal clarity, though graft survival rates in infants and young children are lower than in adults due to a higher risk of rejection and other complications. Management of associated glaucoma may involve medical therapy, surgical procedures such as goniotomy, trabeculotomy, or glaucoma drainage devices. Early intervention is critical to prevent amblyopia, and affected children typically require long-term ophthalmologic follow-up. Optical rehabilitation, including contact lenses and visual aids, may also be necessary to optimize visual outcomes.
Also known as:
Clinical phenotype terms— hover any for plain English:
Variable
Can be inherited in different ways depending on the underlying gene
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Peters anomaly.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Peters anomaly at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Peters anomaly.
Community
No community posts yet. Be the first to share your experience with Peters anomaly.
Start the conversation →Latest news about Peters anomaly
No recent news articles for Peters anomaly.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Peters anomaly
What is Peters anomaly?
Peters anomaly is a rare congenital eye disorder classified as an anterior segment dysgenesis. It is characterized by a central corneal opacity (leukoma) present at birth, along with defects in the posterior layers of the cornea (Descemet membrane and endothelium) and adhesions (synechiae) between the iris and the cornea. The condition primarily affects the anterior segment of the eye and can lead to significant visual impairment or blindness if untreated. Peters anomaly is typically divided into two types: Type I involves central corneal opacity with iridocorneal adhesions but without lens in
At what age does Peters anomaly typically begin?
Typical onset of Peters anomaly is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Peters anomaly?
1 specialists and care centers treating Peters anomaly are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.